Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 3
1970 5
1971 10
1972 7
1973 5
1974 4
1975 4
1976 3
1977 4
1978 1
1980 2
1981 2
1982 3
1983 2
1984 1
1985 4
1986 3
1987 4
1988 2
1989 5
1990 1
1991 2
1996 1
1997 5
1998 5
2001 5
2002 6
2003 4
2004 5
2005 5
2006 4
2007 5
2008 1
2009 2
2010 5
2011 6
2012 10
2013 11
2014 6
2015 6
2016 9
2017 13
2018 14
2019 8
2020 11
2021 22
2022 18
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Among authors: herishanu y. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: herishanu y. Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1. Leukemia. 2022. PMID: 34974526 Free PMC article. No abstract available.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
CLL and COVID-19: light at the end of the tunnel?
Scarfò L, Herishanu Y. Scarfò L, et al. Among authors: herishanu y. Blood. 2022 Aug 4;140(5):407-409. doi: 10.1182/blood.2022017071. Blood. 2022. PMID: 35925645 Free PMC article. No abstract available.
Cefuroxime-induced encephalopathy.
Herishanu YO, Zlotnik M, Mostoslavsky M, Podgaietski M, Frisher S, Wirguin I. Herishanu YO, et al. Neurology. 1998 Jun;50(6):1873-5. doi: 10.1212/wnl.50.6.1873. Neurology. 1998. PMID: 9633748
CD84 mediates CLL-microenvironment interactions.
Marom A, Barak AF, Kramer MP, Lewinsky H, Binsky-Ehrenreich I, Cohen S, Tsitsou-Kampeli A, Kalchenko V, Kuznetsov Y, Mirkin V, Dezorella N, Shapiro M, Schwartzberg PL, Cohen Y, Shvidel L, Haran M, Becker-Herman S, Herishanu Y, Shachar I. Marom A, et al. Among authors: herishanu y. Oncogene. 2017 Feb 2;36(5):628-638. doi: 10.1038/onc.2016.238. Epub 2016 Jul 25. Oncogene. 2017. PMID: 27452524
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now.
Chatzikonstantinou T, Herishanu Y, Montserrat E, Ghia P, Cuneo A, Foà R, Scarfò L. Chatzikonstantinou T, et al. Among authors: herishanu y. Cancer J. 2021 Jul-Aug 01;27(4):328-333. doi: 10.1097/PPO.0000000000000535. Cancer J. 2021. PMID: 34398560 Review.
CD74 is a novel transcription regulator.
Gil-Yarom N, Radomir L, Sever L, Kramer MP, Lewinsky H, Bornstein C, Blecher-Gonen R, Barnett-Itzhaki Z, Mirkin V, Friedlander G, Shvidel L, Herishanu Y, Lolis EJ, Becker-Herman S, Amit I, Shachar I. Gil-Yarom N, et al. Among authors: herishanu y. Proc Natl Acad Sci U S A. 2017 Jan 17;114(3):562-567. doi: 10.1073/pnas.1612195114. Epub 2016 Dec 28. Proc Natl Acad Sci U S A. 2017. PMID: 28031488 Free PMC article.
247 results